Posted in | News | Nanobusiness

Nanoviricides on Track with Drug Candidates for Highly Pathogenic Influenzas Including The H5N1 Bird Flu Avian Influenza and Common Influenza

NanoViricides, Inc., reported today that they are on course with the development of nanoviricides™ drug candidates against highly pathogenic avian influenzas (HPAI) including H5N1 bird flu, and common influenza. “We are now ready to begin animal studies on H5N1 at a renowned federal agency," said Dr. Eugene Seymour, MD, MPH, CEO of the Company. Earlier, the Company had delayed these studies in search of suitable facilities. The work is expected to begin once the contracts are finalized.

Bird Flu H5N1 continues to spread over ever-widening geographic regions and is a major cause of concern for potential pandemic influenza, according to the WHO. This year so far bird flu has spread into six districts in West Bengal, India, causing 120,000 birds to be culled in just 5 days, and 194,000 people to be screened for bird-flu-like symptoms, reports Times of India on January 21, 2008. A boy died of bird flu in Indonesia, and the H5N1 virus was found as far away as a Ukrainian village of Rivne and also northern part of Iran, reports Voice of America. Various research articles have appeared which make researchers fear the virus could mutate and become significantly transmissible between humans.

There are currently no effective treatments against H5N1, or the class of pandemic threatening viruses called HPAI. “The broad-spectrum FluCide™, and the HPAI-specific FluCide-HP™, are designed using the virus’s host cell-binding features that do not change even when the virus mutates,” says Anil R. Diwan, Ph.D., President of the Company. This feature would potentially make these two drugs the best current treatment options for development, says the Company. Vaccines and Antibodies could lose effectiveness due to mutations. H5N1 resistance to Tamiflu® is well known, and resistance against other existing same-class (neuraminidase inhibitor) drugs such as peramivir and possibly Relenza® could occur due to virus mutations.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 15). Nanoviricides on Track with Drug Candidates for Highly Pathogenic Influenzas Including The H5N1 Bird Flu Avian Influenza and Common Influenza. AZoNano. Retrieved on April 17, 2024 from https://www.azonano.com/news.aspx?newsID=5729.

  • MLA

    NanoViricides, Inc. "Nanoviricides on Track with Drug Candidates for Highly Pathogenic Influenzas Including The H5N1 Bird Flu Avian Influenza and Common Influenza". AZoNano. 17 April 2024. <https://www.azonano.com/news.aspx?newsID=5729>.

  • Chicago

    NanoViricides, Inc. "Nanoviricides on Track with Drug Candidates for Highly Pathogenic Influenzas Including The H5N1 Bird Flu Avian Influenza and Common Influenza". AZoNano. https://www.azonano.com/news.aspx?newsID=5729. (accessed April 17, 2024).

  • Harvard

    NanoViricides, Inc. 2019. Nanoviricides on Track with Drug Candidates for Highly Pathogenic Influenzas Including The H5N1 Bird Flu Avian Influenza and Common Influenza. AZoNano, viewed 17 April 2024, https://www.azonano.com/news.aspx?newsID=5729.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.